Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nerdwallet Inc (NRDS) vs Zoetis Inc (ZTS) Price & Performance

Nerdwallet IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Nerdwallet Inc vs Zoetis Inc — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $625.17M), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 49.8× Nerdwallet Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

NRDSZTS
Market Cap
$625.17M$31.14B
Sector
FinancialsHealth
52-Week High
$15.93$156.76
52-Week Low
$7.58$71.91
Enterprise Value
$539.47M$38.70B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.

NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.

Zoetis Inc

Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.

The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.

Returns comparison

Trailing returns across standard periods

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS